ArticleBMC research notes2025
Microbial prevalence and understanding of their antimicrobial susceptibility in urinary tract of patients attending at shar teaching hospital (2018-2022).
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUrinary Tract Infections (UTIs) are among the most common microbial infections in humans globally, a leading cause for medical consultation, and the main contributor to antibiotic consumption. This study aimed to determine the microbial prevalence of UTIs and assess the antibacterial susceptibility patterns of uropathogenic microbial pathogens over a five-year period.
methodThis retrospective research was done from June 2018 to 2022. The following E. coli, Klebsiella spp., fungi, Pseudomonas spp., Staphylococcus spp., Acinetobacter spp., and Enterococcus spp. microbes were identified from 3,330 midstream urine samples. The microbes were identified following standard microbiological techniques. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion technique and the VITEK
findingsThe prevalence of UTI among patients attending Shar Hospital was 927 (27.9%). The most prevalent bacteria were E. coli (56.7%), followed by Klebsiella spp. (10.7%), Pseudomonas spp. (8.2%), Staphylococcus spp. (6.3%), Acinetobacter spp. (3.9%), Enterococcus spp. (3.3%), and fungi (10.7%). Some of the microbes exhibited high resistance to commonly used antibiotics such as ciprofloxacin, whereas they showed high efficacy against meropenem, nitrofurantoin, and amikacin. Furthermore, certain antibiotics including amoxiclav and ceftazidime showed gender-specific differences, presenting statistically significant differences in susceptibility between genders.
conclusionThe current data highlights the prevalence of antimicrobial resistance in UTIs. Routine antimicrobial responsible management programs need to be performed to optimize antibiotic use, standardized surveillance protocols, and evidence-based recommendations for suitable antibiotic selection. These measures can assist enhancing efficacy and decreasing the development of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.